BridgeBio Pharma (BBIO) EBITDA (2018 - 2026)
BridgeBio Pharma (BBIO) posted EBITDA of -$106.0 million for Q1 2026, up 24.08% sequentially from -$139.6 million in Q4 2025, and down 1.52% YoY from -$107.6 million in Q1 2025.
BridgeBio Pharma (BBIO) EBITDA (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported EBITDA for 9 years, with the latest figure at -$106.0 million in Q1 2026.
- Quarterly EBITDA fell 1.52% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$525.0 million (up 24.75% YoY) and the FY2025 annual result came in at -$523.4 million, up 11.73% from the prior year.
- EBITDA improved to -$106.0 million in Q1 2026 per BBIO's latest filing, from -$139.6 million in the prior quarter.
- Over five years, EBITDA peaked at $343000.0 in Q1 2024 and troughed at -$226.0 million in Q4 2024.
- A 5-year average of -$137.8 million and a median of -$139.6 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA jumped 100.27% in 2024, then plunged 30529.15% in 2025.
- Over 5 years, EBITDA stood at -$129.2 million in 2022, then plunged by 37.28% to -$177.4 million in 2023, then retreated by 27.4% to -$226.0 million in 2024, then jumped by 38.25% to -$139.6 million in 2025, then advanced by 24.08% to -$106.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$106.0 million, -$139.6 million, and -$145.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -107.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -107.08 Mn |
| Mar 31, 2026 | -105.96 Mn |
| Dec 31, 2025 | -139.56 Mn |
| Sep 30, 2025 | -145.20 Mn |
| Jun 30, 2025 | -134.28 Mn |
| Mar 31, 2025 | -104.37 Mn |
| Dec 31, 2024 | -226.03 Mn |
| Sep 30, 2024 | -191.75 Mn |
| Jun 30, 2024 | -175.54 Mn |
| Mar 31, 2024 | 343,000.00 |
| Dec 31, 2023 | -177.42 Mn |
| Sep 30, 2023 | -157.69 Mn |
| Jun 30, 2023 | -146.10 Mn |
| Mar 31, 2023 | -126.16 Mn |
| Dec 31, 2022 | -129.23 Mn |
| Sep 30, 2022 | -129.12 Mn |
| Jun 30, 2022 | -80.18 Mn |
| Mar 31, 2022 | -173.68 Mn |
| Dec 31, 2021 | -165.61 Mn |
| Sep 30, 2021 | -149.50 Mn |